passages: 1
passages: document
passages: Comparison of budesonide Turbuhaler with budesonide aqua in the treatment of seasonal allergic rhinitis . Rhinocort Study Group . OBJECTIVE To compare the effect of budesonide Turbuhaler 400 microg/day with budesonide aqua 256 microg/day in the treatment of seasonal allergic rhinitis ( SAR ) . Secondarily to ascertain patients ' preferences for the two nasal devices and to assess quality of life . DESIGN Randomized , multicentre , double-blind , double- dummy , parallel groups study . SETTING Private practices and hospital clinics in Ontario , Quebec and Manitoba . POPULATION Two hundred and eighty-four out-patients with SAR , who were symptomatic during the ragweed season , volunteered for enrolment ( 243 randomized ) . RESULTS Mean daily nasal symptom scores were significantly reduced with treatment . There were no statistically significant changes from baseline for eye symptoms . Most patients ( more than 80 % ) achieved substantial control of their symptoms with budesonide . The most common nasal and non-nasal adverse events for both groups were epistaxis and headache . Turbuhaler was easier to use and more convenient to carry , had less of an unpleasant taste , and caused less nasal irritation than the aqua spray . More than twice as many patients preferred Turbuhaler to the aqua spray ( 69 % versus 31 % ) . Improvement in quality of life from baseline to clinic visits was statistically significant in both groups . CONCLUSION Once daily use of 256 mg of budesonide aqua and 400 mg of budesonide Turbuhaler are equally safe and efficacious in the treatment of SAR . Patients preferred the budesonide powder formulation delivered via Turbuhaler two to one over the aqua formulation .
entities: 2
entities: Intervention_Pharmacological
entities: budesonide Turbuhaler
entities: 3
entities: Intervention_Pharmacological
entities: budesonide aqua
entities: 4
entities: Intervention_Pharmacological
entities: budesonide Turbuhaler
entities: 5
entities: Intervention_Pharmacological
entities: budesonide aqua
entities: 6
entities: Intervention_Pharmacological
entities: budesonide .
entities: 7
entities: Intervention_Pharmacological
entities: Turbuhaler
entities: 8
entities: Intervention_Pharmacological
entities: Turbuhaler
entities: 9
entities: Intervention_Pharmacological
entities: aqua spray
entities: 10
entities: Intervention_Pharmacological
entities: budesonide aqua
entities: 11
entities: Intervention_Pharmacological
entities: budesonide Turbuhaler
entities: 12
entities: Intervention_Pharmacological
entities: budesonide powder
entities: 13
entities: Intervention_Pharmacological
entities: Turbuhaler
entities: 14
entities: Intervention_Pharmacological
entities: aqua
entities: 15
entities: Outcome_Other
entities: patients ' preferences
entities: 16
entities: Outcome_Other
entities: quality of life
entities: 17
entities: Outcome_Physical
entities: .
entities: 18
entities: Outcome_Physical
entities: Mean daily nasal symptom scores
entities: 19
entities: Outcome_Physical
entities: eye symptoms .
entities: 20
entities: Outcome_Adverse-effects
entities: nasal and non-nasal adverse events
entities: 21
entities: Outcome_Adverse-effects
entities: epistaxis
entities: 22
entities: Outcome_Adverse-effects
entities: headache .
entities: 23
entities: Outcome_Other
entities: nasal irritation
entities: 24
entities: Outcome_Other
entities: quality of life
entities: 25
entities: Outcome_Other
entities: safe
entities: 26
entities: Outcome_Other
entities: efficacious
entities: 27
entities: Participant_Condition
entities: seasonal allergic rhinitis .
entities: 28
entities: Participant_Sample-size
entities: Two hundred and eighty-four
entities: 29
entities: Participant_Condition
entities: out-patients
entities: 30
entities: Participant_Condition
entities: SAR
entities: 31
entities: Participant_Condition
entities: symptomatic during the ragweed season
entities: 32
entities: Participant_Sample-size
entities: 243
entities: 33
entities: Participant_Condition
entities: SAR .